Skip to main content
Onxeo logo

Onxeo — Investor Relations & Filings

Ticker · ALONX ISIN · FR0010095596 LEI · 96950018AS30IUG0V528 PA Manufacturing
Open in API
Filings indexed 661 across all filing types
Latest filing 2015-05-20 Regulatory Filings
Country FR France
Listing PA ALONX

About Onxeo

https://www.onxeo.com/

Valerio Therapeutics, formerly Onxeo, is a biotechnology company developing next-generation precision-guided therapies for complex and underserved diseases. The company's core technology is its proprietary V-Body platform, which is based on two fully synthetic single-domain antibody (sdAb) libraries. This platform is engineered to create advanced drug conjugates that enable deep tissue penetration and highly precise therapeutic delivery. By integrating innovative target identification, antibody engineering, and cutting-edge linker and payload technologies, Valerio Therapeutics aims to develop treatments with superior efficacy and target engagement. The company's strategy involves advancing its therapeutic candidates to key development milestones before pursuing strategic partnerships for co-development and out-licensing.

Recent filings

Filing Released Lang Actions
Information relating to the total number of voting rights and shares making up the capital
Regulatory Filings Classification · 1% confidence The document explicitly discloses the "total number of voting rights and number of shares in the capital" as of a specific date (April 30, 2015), referencing French commercial code and AMF regulations. This type of mandatory disclosure regarding the total share capital and voting rights is a specific regulatory filing requirement, often related to changes in ownership structure or capital base. It is not a full annual report (10-K), an earnings release (ER), or a dividend notice (DIV). Since it deals directly with the number of shares and voting rights, it most closely aligns with announcements related to capital structure or major shareholding notifications. Given the context of mandatory regulatory disclosure regarding the total number of shares and voting rights, it fits best under the general regulatory filing category (RNS) or potentially a specific capital/share announcement. However, since it is a formal disclosure of the total share count required by market authorities, and doesn't fit perfectly into DVA (which is about *results* of a vote) or SHA (which is about *issuance*), RNS (Regulatory Filings) serves as the most appropriate general regulatory category for this specific, periodic capital structure disclosure, although it is highly specific. Upon re-evaluation against the definitions, it is a formal regulatory disclosure of capital structure information. It is not a Director's Dealing (DIRS), Major Shareholding Notification (MRQ - which is about *changes* by an *investor* crossing a threshold), or Share Issue (SHA - which is about *creating* new shares). Therefore, RNS is the best fit as a mandatory regulatory disclosure that doesn't match other specific codes.
2015-05-20 English
Communicated under the obligation to provide permanent information / Other communications
AGM Information Classification · 1% confidence The document explicitly discusses the 'Combined General Meeting of Shareholders' held on May 20, 2015, and states that 'the General Meeting... adopted all of the resolutions recommended by the Board of Directors.' Crucially, it then directs the reader to where the 'voting results of the Combined General Meeting are available.' This content is focused on the outcome and results of a shareholder vote following a general meeting, which aligns perfectly with the definition of 'Declaration of Voting Results & Voting Rights Announcements' (DVA). It is not the AGM presentation itself (AGM-R), nor is it a general proxy solicitation (PSI).
2015-05-20 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
AGM Information Classification · 1% confidence The document explicitly mentions "Assemblée Générale Mixte d'Onxeo" (Mixed General Meeting of Onxeo) and states that the meeting was held and approved all resolutions. It also directs the reader to where the voting results can be found. This content directly relates to the proceedings and outcomes of a General Meeting. Therefore, the most appropriate classification is AGM Information (AGM-R). The document length (3052 chars) is substantial enough to be the primary announcement, not just a brief RPA.
2015-05-20 French
Communicated under the obligation to provide permanent information / Other communications
Report Publication Announcement Classification · 1% confidence The document explicitly announces the 'Publication of a Letter to Shareholders – May 2015' and directs the reader to the company website to view it. The document itself is short (2476 characters) and serves as an announcement rather than the full content of the letter or a comprehensive financial report (like 10-K or IR). This fits the definition of a Report Publication Announcement (RPA), which covers announcements regarding the release or publication of company reports. Although 'Letter to Shareholders' might suggest other categories, the primary action described is the announcement of the publication, making RPA the most appropriate classification based on the 'MENU VS MEAL' rule.
2015-05-12 English
Communiqués au titre de l'obligation d'information permanente / Autres communiqués
Report Publication Announcement Classification · 1% confidence The document is titled "Publication de la Lettre aux Actionnaires – Mai 2015" (Publication of the Letter to Shareholders – May 2015). The text explicitly states: "Onxeo SA... annonce la publication ce jour de sa Lettre aux Actionnaires de mai 2015." (Onxeo SA... announces the publication today of its Letter to Shareholders of May 2015.) Furthermore, it directs the reader to the company website to find the actual letter. Given the very short length (2792 characters) and the content being an announcement about the release of another document (a shareholder letter), this fits the definition of a Report Publication Announcement (RPA). Although 'LTR' (Legal Proceedings Report) or 'IR' (Interim Report) might seem related to shareholder communications, the primary action described is the *announcement of publication* of a specific document, making RPA the most accurate classification based on Rule 2.
2015-05-12 French
Communicated under the obligation to provide permanent information / Other communications
Regulatory Filings Classification · 1% confidence The document is an announcement from Onxeo S.A. stating that results from their Validive® Phase II clinical trial have been accepted for an oral presentation at the MASCC/ISOO International Symposium. It details the context of the presentation, summarizes previous positive results, and discusses the implications for future Phase III trials. This is not a full financial report (10-K or IR), an earnings release (ER), or a management discussion (MDA). It is an announcement regarding scientific/clinical data presentation, which falls under general investor relations communication. Since there is no specific category for clinical trial result announcements, and it is a formal press release detailing company progress and future plans, it best fits the general 'Regulatory Filings' (RNS) category as a miscellaneous, non-standard regulatory/investor announcement, or potentially an Investor Presentation (IP) if it were the presentation itself, but here it is the *announcement* of the presentation. Given the options, RNS is the most appropriate fallback for a press release about clinical trial acceptance for presentation.
2015-05-06 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.